Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy

Central Serous Chorioretinopathy Clinical Trial

Official title:

A Prospective Study of the Use of Micropulse 577nm Laser Treatment in Central Serous Chorioretinopathy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01982383
• Other study ID #: 021236
• Status: Terminated
• Phase: N/A
• First received: November 6, 2013
• Last updated: March 1, 2018
• Start date: November 2012
• Est. completion date: November 2015

Study information

• Verified date: March 2018
• Source: George Washington University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators hypothesis is that using the micropulse laser in patient with Central Serous Chorioretinopathy (CSC) will prompt resolution of CSC and will be effective in significantly minimizing visual recovery time from this disease as well as potentially preventing recurrences.

Description:

The investigators hypothesize that application of 577nm micropulse laser in patients with CSC will prompt resolution of CSC as measured by ocular coherence tomography and best corrected visual acuity. This will be a pilot study to establish sound methods and provide some insights to the safety and efficacy of CSC treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: November 2015
• Est. primary completion date: November 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 60 Years

Eligibility

Inclusion Criteria:

• Patients with new diagnosis of CSC and no other comorbidities or prior retinal treatment

• Patients ranging from 30 to 60 years of age

Exclusion Criteria:

• Patients with no case of CSC

• Patients with other macular comorbidities including but not limited to diabetic retinopathy, macular degeneration

• Patients with prior retinal treatment

Related Conditions & MeSH terms

• Central Serous Chorioretinopathy

Intervention

Device:
• Micropulse Laser Treatment

Other:
• No treatment

Locations

Country	Name	City	State
United States	George Washington University Medical Faculty Associates	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
George Washington University

Country where clinical trial is conducted

United States, 

References & Publications (3)

Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008 Dec;115(12):2229-34. doi: 10.1016/j.ophtha.2008.08.026. — View Citation

Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol. 2008 Nov-Dec;18(6):934-40. — View Citation

Ricci F, Missiroli F, Cerulli L. Indocyanine green dye-enhanced micropulsed diode laser: a novel approach to subthreshold RPE treatment in a case of central serous chorioretinopathy. Eur J Ophthalmol. 2004 Jan-Feb;14(1):74-82. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Resolution of Fluid Build-up	Central Serous Choroidopathy is a disease that causes fluid to build up under the retina,the back part of the inner eye that sends sight information to the brain. The objective here is to apply 577nm of micropulse laser to see if CSC resolution occurs and measuring it through ocular coherence tomography (retinal imaging), vision score, and visual field testing for retinal sensitivity.	within 1 week to 3 months after the laser procedure is completed